FII-INSTITUTE
Population projections stress the need for sustainable living on our planet and on others. FII Institute announces today an investment in Interstellar Lab, a space technology company designing closed loop biodomes for sustaining life on Earth, the moon, and Mars.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005919/en/
FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. The $500,000 USD equity investment is a part of Interstellar Lab's latest $3M USD Seed Round and builds on FII Institute's commitment to catalyze globally relevant, real-world solutions in Artificial Intelligence and Robotics, Education, Healthcare and Sustainability. Through the investment, the Institute will fund the development of, and leverage, AI simulation-based designs to tackle Earth’s most pressing environmental issues, paving the way to solutions in waste management, zero-impact living and resource-conscious agriculture.
“Climate change is a real emergency for Earth, and we only have a small window to bring about positive change. We are developing a new framework for sustainable living on Earth and a testbed for future space missions,” Barbara Belvisi, Founder and CEO, Interstellar Lab said. “Working with investors like FII Institute advances Interstellar Lab’s mission to support human life sustainably on Earth, the moon and Mars by generating and recycling food, water and air.”
FII Institute CEO Richard Attias said, "Space sector growth is creating new opportunities for advanced research and solutions in sustainability. Inspired by the design challenge of human settlement on Mars, Interstellar Lab has forged an innovative approach to sustaining life in the absence of the abundance taken for granted here on Earth. We are very pleased to support the technologies that will help reduce the burden on our planet and prepare us for the future."
This marks the third FII Institute investment this year following announcements to back Lilium, an electric-powered aircraft reducing the carbon impact of regional travel, and Red Sea Farms, AgTech making it possible to grow food using saltwater. With an inclusive agenda built on three pillars – THINK, XCHANGE, ACT – FII Institute empowers the brightest minds to leverage scientific innovation for positive change, brings leading solutions to reality through investment, and calls for global collaboration in the service of humanity.
About FII Institute (Future Investment Initiative Institute)
FII Institute is a global non-profit foundation with an investment arm and one agenda: Impact on Humanity. Committed to Environmental, Social and Governance (ESG) principles, we foster the brightest minds and transform ideas into real-world solutions.
When decision makers, investors and an engaged generation of youth come together, energized and ready for change, we harness that energy into three pillars – THINK, XCHANGE, ACT – and invest in the innovations that make a difference to lives globally.
About Interstellar Lab
Interstellar Lab is developing and building closed-loop sustainable living systems on Earth and in space. The company focuses on creating space-grade food production systems and habitat modules. The aim is double: to provide solutions regarding the current climate crisis and the need of new food production systems on Earth, and to develop closed-loop life support systems for lunar missions in the context of NASA’s Artemis Program and in the future for Mars exploration.
*Source : AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005919/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom